HER2/is an oncogene expressed in approximately 20% of all breast cancer patients. It encodes for transmembrane receptors of growth factors that are responsible for activating subcellular signal transduction pathways controlling epithelial cell growth and differentiation; hence, the gene plays an important ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
In the initialtrial, 406 patients withHER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received weekly paclitaxel plus weekly trastuzumab for 12 weeks, followed by trastuzumab every 3 weeks for 9 months. (There wasn’t a control group because no standard of trea...
milestones, and a review of HER2-positive breast cancer. Detailed clinical profiles of select drugs of interest can be found in the separate Dashboard report. Clinical, regulatory, and other updates will be made to the Dashboard on a monthly basis. ...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types of cancer, including advanced gastric an
Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We ...
Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies.
This program is currently inactive. In the meantime, please visitGenentech Patient Support Servicesto learn about the resources available for individuals prescribed Genentech medicines. Our programs are designed to assist you based on your specific needs and situation....
Breast cancer is one of the major public health problems, being the number one cause of cancer in women and the second leading cause of cancer death in the United States1. It has been shown that ap...